EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (Amex: AIS) announced that a new broad patent has been issued covering its ATD™ (Advanced Transdermal Delivery) gel formulations used in Anturol® (oxybutynin), Elestrin™ (estradiol) and LibiGel® (testosterone) as well as future products in our ATD gel system. Antares is the sole owner of Anturol and the newly issued patent. Named inventors on this new patent are from both Antares and our licensee, BioSante Pharmaceuticals.
